Protect staff, patients & customers from dangerous pathogens with our Viraclean disinfectant spray. Proven to kill 99.999% of germs.
Whiteley’s Viraclean disinfectant spray has proven efficacy tested across a range of viruses. Our disinfectant spray also actively eliminates bacteria and kills germs on surfaces. For critical area cleaning, disinfecting, and infection control applications, disinfectant spray is a crucial addition to remove harmful germs by cleaning and disinfecting in a single step.
Our best-selling disinfectant spray is available to purchase directly from our online store in convenient multipacks and bundles.
Surface disinfection is a critical practice for cleaning surface areas contaminated with pathogens. Whiteley’s Viraclean disinfectant spray is very effective against a range of bacteria. On key surface areas, such as high touch points, disinfectant sprays kill bacteria and germs, ensuring bacterial growth is minimised. Ensuring surfaces are clean and disinfected from harmful germs is a key step to minimise the risk of infection within your workplace. Available in a convenient and easy to use spray bottle, our disinfectant spray is a convenient and simple way to eliminate germs.
There are 3 simple steps you can take to reduce the spread of pathogens
Step 1 – Effective Surface Cleaning & Disinfection
Regular, effective surface cleaning, with hospital grade disinfectants will assist in protecting staff and patients.
Step 2 – Good Hand Hygiene
Ensuring quality hand sanitisers are easily accessible in waiting rooms and practice rooms will assist in minimising the risk of infection transmission.
Step 3 – Infection Prevention Education & Training
Whiteley understands the importance of infection prevention and has developed a range of products and educational programs to reduce the spread of HAIs. The Whiteley disinfectant spray range includes Viraclean a premium quality TGA registered hospital-grade disinfectant.
Answer: A disinfectant spray is a type of cleaning solution that is designed to kill germs, bacteria, and viruses on surfaces. It works by using chemicals that penetrate the cell walls of microorganisms and destroy them.
Disinfectant spray can be used across a range of different hard surfaces, with a focus on high-touch point areas. Examples of common areas to disinfect include countertops, floors and walls, door handles, light switches, exercise equipment and medical equipment. The correct way to disinfect surfaces depends on the instructions located on the disinfectant spray labels. It is important to also check material compatibility to ensure that the correct use of disinfectant spray is adhered to.
Answer: The frequency of disinfectant spray use can vary depending on the surface and the level of contamination. In general, high-touch surfaces such as doorknobs, light switches, and countertops should be disinfected daily, while other surfaces may only need to be disinfected once a week.
Answer: Disinfectant sprays contain explicit instruction to avoid ingestion and inhalation, it is therefore important to keep away from children and pets. Some disinfectant sprays may also contain harsh chemicals that can be harmful to pets and children. Be sure to read the label of your disinfectant spray and follow the instructions carefully.
Answer: Whiteley, an Australian-based e-commerce company, is a trusted provider of top-quality disinfectant sprays for both household and professional use. With a wide range of formulations and sizes available for selection on the website, you can easily find the best product to meet your needs. Trust Whiteley for your disinfectant needs and ensure a clean and healthy environment.
Whiteley offers advice, training and practical support for all of your infection prevention, medical device reprocessing, and professional cleaning needs.
You can view our product safety data sheets, technical bulletins and find out about the products from our range.
Speaker: Doctor Arthika Manoharan
Qualifications: Postdoctoral Research Fellow at University of Sydney
Speaker Profile:
Arthika is a Postdoctoral Research Fellow at The University of Sydney Infectious Diseases Institute, having recently completed her PhD in collaboration with Whiteley Corporation, under the supervision of Dr. Theerthankar Das and A/Prof Jim Manos. Her research aims to tackle biofilm formation in recurrent and catheter associated urinary tract infections, using antioxidants to circumvent antibiotic resistance and decipher how these antioxidants influence host-pathogen interactions in the bladder. A microbiologist with extensive immunology experience, Arthika has worked in various projects ranging from studying CAR T cells to antibiotic resistant biofilms. With 6 publications under her belt, Arthika is an enthusiastic early career researcher interested in multidisciplinary research that combines fundamental and translational sciences. She is also an avid advocate for EMCRs in the medical sciences, having served extensively on various EMCR committees university wide and in professional bodies, including ASM.
Topic: Rethinking biofilm treatments in catheter associated urinary tract infections
Presentation Outline: Catheter-associated urinary tract infections are a major issue in hospitals and age-care facilities. Biofilm formation in catheters can often result in encrustation and occlusion of the catheter, resulting in lack of urinary drainage and severe dissemination of infection. In my research, we investigated the novel effects of N-acetyl cysteine (NAC) on biofilm formation and matrix disruption using an in vitro glass bladder model. Furthermore, we also investigate the influence of NAC in host pathogen interactions, to elucidate how we can influence host cellular interactions to enhance biofilm removal.
Speaker: Professor Slade Jensen
Qualifications: B.Med.Sc. (USyd) PhD. (USyd). FASM
Speaker Profile:
Slade is a Professor of Microbiology and Infectious Diseases in the School of Medicine, Western Sydney University and Research Director of the Antibiotic Resistance and Mobile Elements Group, and the Limb Preservation and Wound Research Group, both of which are based at the Ingham Institute for Applied Medical Research. He obtained a Ph.D. from the University of Sydney focused on the role of horizontal gene transfer in bacterial evolution. His current research interests include the development of novel antimicrobials, the evolution of antibiotic resistance in hospital pathogens, such as ‘Golden Staph’, and the role of host-microbe interactions in disease progression, particularly in the context of diabetes-related foot ulcers.
Topic: Microbes, biofilms and diabetes-related foot ulcers
Presentation Outline: Slade will discuss how his team’s research has assisted in changing the understanding of the pathology of chronic ulceration in diabetic foot infections, from that of infection with planktonic bacteria to that of infection with biofilm. Due to the resistance of biofilms to antimicrobial penetration, increased emphasis is now given to removal of adequate volumes of tissue with debridement and the use of anti-biofilm compounds.
Speaker: Professor Kate Moore
Qualifications: MB BS Syd, MD Liv, FRCOG, FRANZCOG, CU
Speaker Profile:
Arthika is a Postdoctoral Research Fellow at the University of Sydney, having recently completed her PhD in collaboration with Whiteley Corporation, under the supervision of Dr. Theerthankar Das and A/Prof Jim Manos. Her research aims to tackle biofilm formation in recurrent and catheter associated urinary tract infections, using antioxidants to circumvent antibiotic resistance and decipher how these antioxidants influence host-pathogen interactions in the bladder. A microbiologist with extensive immunology experience, Arthika has worked in various projects ranging from studying CAR T cells to antibiotic resistant biofilms. With 6 publications under her belt, Arthika is an enthusiastic early career researcher interested in multidisciplinary research that combines fundamental and translational sciences. She is also an avid advocate for EMCRs in the medical sciences, having served extensively on various EMCR committees university wide and in professional bodies, including ASM.
Topic: Rethinking biofilm treatments in catheter associated urinary tract infections
Presentation Outline: Catheter-associated urinary tract infections are a major issue in hospitals and age-care facilities. Biofilm formation in catheters can often result in encrustation and occlusion of the catheter, resulting in lack of urinary drainage and severe dissemination of infection. In my research, we investigated the novel effects of N-acetyl cysteine (NAC) on biofilm formation and matrix disruption using an in vitro glass bladder model. Furthermore, we also investigate the influence of NAC in host pathogen interactions, to elucidate how we can influence host cellular interactions to enhance biofilm removal.
Speaker: Associate Professor Greg Whiteley
Qualifications: FEHA, MASM, MSHEA, PhD, M Safety Sc, B App, Dip AICD
Speaker Profile:
Dr Greg Whiteley is an Adjunct Associate Professor in the Faculty of Medicine and Health at the University of Sydney, a Fellow in the School of Medicine at Western Sydney University and is also the Executive Chairman of Whiteley Corporation. Assoc. Prof Whiteley’s qualifications include a Bachelor of Applied Science (Hawkesbury Agricultural College), a Master of Safety Science (University of New South Wales), a Diploma from the Australian Institute of Company Directors (University of New England) and a PhD (Western Sydney University).
Dr Whiteley is a Life Fellow of Environmental Health Australia, a Member of the Society of Healthcare Epidemiology of America and is a Member of the Australian Society of Microbiology. He currently serves as a director of the trade association known as ACCORD Australia, and also as an expert consultant to the Infection Control Committee for the Australian Dental Association. He has previously served on HE-023 with Standards Australia.
His on-going research interests focus on biofilms found within healthcare settings, healthcare hygiene and the cleanliness of medical devices. Findings from this research team include publications outlining the extent of biofilm problems within healthcare and other settings, monitoring solutions including ATP testing, and extensive findings on the cleaning and disinfecting implications from biofilms on healthcare surfaces and reusable medical devices.
Dr Whiteley has previously been an Industry Partner for an ARC Grant in conjunction with Macquarie University, a Collaboration Partner Study Director for an iMCRC Grant with the School of Medicine at Sydney University, the Study Director of a CRC-P Grant investigating novel diagnostic and treatment options for wound care co-jointly partnering with AMP Control and the University of Newcastle and Western Sydney University.
Dr Whiteley is currently the Executive Chairman of Whiteley Corporation. He bears ultimate responsibility under Commonwealth Legislation for the Therapeutic Goods registrations and the manufacturing license of the manufacturing location in Tomago. Dr Whiteley has additionally co-authored many patents and peer reviewed publications.
Topic: Advances in Biofilm TestingÂ
Presentation Outline: This topic will provide an overview into key lessons and research findings on dry surface and wet surface biofilms and their impact on critical healthcare departments. Published research on the presence of biofilms containing viable multi-resistant organisms and the critical role of rigorous cleaning processes to prevent hospital acquired infections (HAI’s). Understanding why cleaning protocols must adapt to account for our new logic of the role of biofilms in bacterial survival and transmission of infections.
Stay updated on special offers, new product updates, helpful information and more.
*Terms and conditions: 10% discount offer valid for first order only, over the value of $100.00.
Free shipping will also apply for orders over $99.00.